Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
09/2007
09/04/2007US7265124 Cristalline and amorphous form of a triazolo (4,5-D) pyridimine compound
09/04/2007US7265120 Pyrazine derivatives and pharmaceutical use thereof
09/04/2007US7265119 For therapy of nicotine dependency
09/04/2007US7265116 Attention deficit disorders; hyperactivity; post-trauma stress disorders; anxiolytic agents; obsessive compulsive disorders; analgesics; Parkinson's disease
09/04/2007US7265115 Central nervous system-active cholinergic ligands for neuronal nicotinic receptors; Controlling synaptic transmission; selectively controlling neurotransmitter release; a (halopyridazinyl)-3,8-diazabicyclo(3.2.1)octane
09/04/2007US7265113 Anticancer agents; antiinflammatory agents, for therapy of rheumatoid arthritis
09/04/2007US7265110 Psychological disorders; antidepressants; anxiolytic agents; analgesics; antiinflammatory agents; central nervous system disorders
09/04/2007US7265108 For example, 6-[2-[4-(2-fluorophenoxymethyl)piperidino]ethyl]-1H-pyrazin-2-one; therapeutic or prophylactic agent for diabetic neuralgia, HIV neuralgia, postherpetic neuralgia, nerve system disorders
09/04/2007US7265106 Chromatography; separation of enantiomorphs
09/04/2007US7265103 For therapy of depression, anxiety and body weight disorders
09/04/2007US7265099 Use of chemical chelators as reversal agents for drug-induced neuromuscular block
09/04/2007US7264810 Scaffolds comprising epitopes and genetic engineered proteins of bacteriophages, used as vaccines, anticarcinogenic agents or antiallergens
09/04/2007US7264798 Sensitization of chemotherapeutic agent resistant neoplastic cells with a virus
09/04/2007US7264793 Numb protein expression inhibitors by Musashi
09/04/2007CA2450789C Schwann cells originating in myeloid interstitial cells
09/04/2007CA2397828C Compounds having hypolipidemic and hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them
09/04/2007CA2336194C 1-(aminoalkyl)-3-quinoxaline-2-one derivatives for the preparation of compounds having an antioxidant action
09/04/2007CA2329665C Treatment of depression and pharmaceutical preparations therefor
09/04/2007CA2297911C Substituted 6-phenylphenanthridines
09/04/2007CA2283083C Use of 2,3,4,5-tetrahydro-1h-3-benzazepines for the manufacture of a pharmaceutical composition for the treatment of sleep disorders
09/04/2007CA2258044C Muscarinic antagonists
09/04/2007CA2125643C Pharmaceutical composition having analgesic activity
09/01/2007CA2579562A1 Method for improving sleep behaviors
08/2007
08/30/2007WO2007098418A1 Compounds having 5-ht6 receptor affinity
08/30/2007WO2007098417A2 Treatment of alzheimer's disease with inhibitors of apoe binding to apoe receptor
08/30/2007WO2007098386A1 Pyrazolylquinazolinones as potassium channel openers
08/30/2007WO2007098273A2 Novel crystalline forms of armodafinil and preparation thereof
08/30/2007WO2007098214A1 Cinnoline derivatives as phosphodiesterase 10 inhibitors
08/30/2007WO2007097976A1 Process for preparing intermediates to 5-ht4 receptor agonist compounds
08/30/2007WO2007097697A1 Therapeutic quinoline compounds that are 5ht1b modulators
08/30/2007WO2007097251A1 PEPTIDE VACCINE FOR INDUCING PRODUCTION OF ANTI-AMYLOID-β-PEPTIDE ANTIBODY
08/30/2007WO2007096743A1 Substituted quinazolines as pde10 inhibitors
08/30/2007WO2007096694A1 Combination of neuroactivating active principles
08/30/2007WO2007096489A1 Novel pharmaceutical compositions for optimizing replacement treatments and broadening the pharmacopeia for the overall treatment of addictions
08/30/2007WO2007096396A2 Methods for treating autoimmune or demyelinating diseases
08/30/2007WO2007096352A1 5-amino-6-bromo-n-{ [1- (tetrahydr0-2h-pyran-4-ylmethyl) -4-piperidinyl] methyl}-3, 4 -dihydro-2h-chromene-8-carboxamide as 5-ht4 receptor agonist
08/30/2007WO2007096193A2 Radiolabelled carbamates
08/30/2007WO2007096076A2 Anti-amyloid immunogenic compositions, methods and uses
08/30/2007WO2007095756A1 Novel central-nervous system acting compounds and methods for the treatment of cns disorders
08/30/2007WO2007095728A1 The use of deferiprone and methods to treat and/or prevent friedreich ataxia resulting from intracellular mishandling of iron
08/30/2007WO2007079195A3 Gastric retentive gabapentin dosage forms and methods for using same
08/30/2007WO2007079141A9 Method of identifying compounds useful to treat neuronal degenerative diseases
08/30/2007WO2007074238A3 Novel n-alk-(e)-ylidene-n'-pyrimidin-2-yl hydrazine derivatives and use thereof as cytoprotective drugs
08/30/2007WO2007064566A3 Heterocycle-substituted 3-alkyl azetidine derivatives
08/30/2007WO2007056388A9 Compositions and methods for modulating poly (adp-ribose) polymerase activity
08/30/2007WO2007050726A3 Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists
08/30/2007WO2007036802A3 Sublingual dosage form comrising vitamin d analogue, in particular calcitriol
08/30/2007WO2007034329A3 Compounds and methods for treatment of amyloid-beta-peptide related disorders
08/30/2007WO2006063837A8 Use of bombesin/gastrin-releasing peptide antagonists for the treatment of inflammatory conditions, acute lung injury and bipolar disorder
08/30/2007US20070203353 Bipolar trans carotenoid salts and their uses
08/30/2007US20070203338 2-((4,6-dimethoxy)pyrimidin-2-yl-),3-(methoxy-), 3,3-(diphenyl)propionic acid; antihypotensive agents; pulmonary hypertension, mycocardial necrosis; renal failure; brain disorders; antispasmodic agents; antiischemic agents; coagulants; asthma; atherosclerosis; restenosis; Raynaud's syndrome
08/30/2007US20070203337 Use of 2-amino-thiazoline derivatives as inhibitors of inducible no-synthase
08/30/2007US20070203223 Via amino ceramide-like compounds; lowering glycosphingolipid concentrations; Fabry's disease, Gaucher's disease
08/30/2007US20070203197 Phosphodiesterase 4 inhibitors
08/30/2007US20070203192 Saturated and unsaturated 3-pyridyl-benzocycloalkylmethyl-amines for use in treating pain, depression and/or anxiety
08/30/2007US20070203184 Novel Indolin-2-one Derivatives, Their Preparation and the Pharmaceutical Compositions Comprising Them
08/30/2007US20070203152 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
08/30/2007US20070203151 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
08/30/2007US20070203150 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
08/30/2007US20070203141 Method for administering birb 796 bs
08/30/2007US20070203139 Aryl Glycinamide Derivatives And Their Use As Nk1 Antagonists And Serotonin Reuptake Inhibitors
08/30/2007US20070203108 Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
08/30/2007US20070203057 Compounds and methods for modulating adhesion molecule function
08/30/2007US20070202198 Process of obtaining thylakoids from photosynthetic organisms; plant fractions obtained from the process; pure thylakoids; and methods of use of thylakoids as ROS scavengers, photo-protectors, biosensors biofilters and bioreactors
08/30/2007US20070202197 PAWPAW and/or peach derived composition
08/30/2007US20070202181 Low hygroscopic aripipazole drug substance and processes for the preparation thereof
08/30/2007US20070202160 Solid-state form of celecoxib having enhanced bioavailability
08/30/2007US20070202129 Use of the neurotoxic component of a botulinum toxin for the treatment of pain associated with muscle activity or contracture
08/30/2007US20070202100 Using programmed death-1 (PD-1) protein as evaluative tool to identify modulators for treatment and prevention of nervous system, autoimmune, cell proliferative and allergic disorders
08/30/2007US20070202099 Antibody Drug
08/30/2007CA2643983A1 Cinnoline derivatives as phosphodiesterase 10 inhibitors
08/30/2007CA2643048A1 Treatment of alzheimer's disease with inhibitors of apoe binding to apoe receptor
08/30/2007CA2642832A1 Pyrazolylquinazolinones as potassium channel openers
08/30/2007CA2642778A1 The use of deferiprone and methods to treat and/or prevent friedreich ataxia resulting from intracellular mishandling of iron
08/30/2007CA2641670A1 Substituted quinazolines as pde10 inhibitors
08/30/2007CA2638841A1 Anti-amyloid immunogenic compositions, methods and uses
08/30/2007CA2638775A1 Peptide vaccine for inducing production of anti-amyloid-.beta.-peptide antibody
08/30/2007CA2637531A1 Compounds having 5-ht6 receptor affinity
08/30/2007CA2637214A1 Process for preparing 8-azabicylo[3.2.1]octan-3-one intermediates to 5-ht4 receptor agonist compounds
08/30/2007CA2635445A1 Methods for treating autoimmune or demyelinating diseases
08/29/2007EP1825862A1 Method for treating nerve injury and vector construct for the same
08/29/2007EP1824852A1 1,2,3,3a,8,8a-hexahydro-2,7a-diaza-cyclopenta[a]inden-7-one derivatives which bind to neuronal nicotinic acetylcholine specific receptor sites and are useful in modulating cholinergic function and in the treatment of addictive disorders
08/29/2007EP1824848A1 Fused bicycloheterocycle substituted quinuclidine derivatives
08/29/2007EP1824846A2 Novel compounds for the treatment of neurological disorders
08/29/2007EP1824842A2 Inhibitors of 11- hydroxyl steroid dehydrogenase type 1 and methods of using the same
08/29/2007EP1824840A1 Compounds having activity at nk3 receptor and uses thereof in medicine
08/29/2007EP1824837A1 Substituted n-sulfonylaminobenzyl-2-phenoxy acetamide compounds
08/29/2007EP1824830A1 Radiolabelled quinoline-based ligands for the 5-ht6 receptor functionality
08/29/2007EP1824820A2 Substituted tetracyclic tetrahydrofuran,pyrrolidine and tetrahydrothiophene derivatives
08/29/2007EP1824817A1 Arylsulfonylnaphthalene derivatives as 5ht2a antagonists
08/29/2007EP1824496A1 Compositions comprising scyllo-inositol derivatives and methods to treat disorders of protein aggregation
08/29/2007EP1824495A2 Finasteride, dutasteride and related compounds for preventing/treating neurologically-associated disorders
08/29/2007EP1824486A1 Benzdioxane piperazine derivatives with a combination of affinity for dopamine-d2 receptors and serotonin reuptake sites
08/29/2007EP1824480A1 Phenylpiperazine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition
08/29/2007EP1824479A1 Phenylpiperazine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition
08/29/2007EP1824472A1 Use of acetyl l-carnitine for the treatment of fibromyalgic syndrome
08/29/2007EP1824469A1 A method of modulating b cell functioning
08/29/2007EP1824468A2 Glycogen synthase kinase-3 inhibitors
08/29/2007EP1824464A1 Use of a 5-ht6 agonist for the treatment and prevention of neurodegenerative disorders
08/29/2007EP1824462A2 Composition and method for the treatment of tauopathies
1 ... 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 ... 1833